[1] Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline[J]. Fertil Steril,2016,106(7):1634-1647.
[2] Lee TH, Liu CH, Huang CC, et al.Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles[J]. Hum Reprod,2008,23(1):160-167.
[3] Kahnberg A, Enskog A, Brännström M, et al.Prediction of ovarian hyperstimulation syndrome in women under-going in vitro fertilization[J]. Acta Obstet Gynecol Scand,2009,88(12):1373-1381.
[4] Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al.Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles[J]. Fertil Steril,2006,85(1):112-120.
[5] Toftager M, Bogstad J, Bryndorf T, et al.Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles[J]. Hum Reprod,2016,31(6):1253-1264.
[6] Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology[J]. Cochrane Database Syst Rev,2011,(5):CD001750.
[7] Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology[J]. Cochrane Database Syst Rev,2014,(10):CD008046.
[8] Meyer L, Murphy LA, Gumer A, et al.Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles[J]. Fertil Steril,2015,104(3):637-642.
[9] Várnagy A, Bódis J, Mánfai Z, et al.Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome[J]. Fertil Steril,2010,93(7):2281-2284.
[10] Revelli A, Dolfin E, Gennarelli G, et al.Low-dose acetylsalicylic acid plus prednisolone as an adjuvant treatment in IVF: a prospective, randomized study[J]. Fertil Steril,2008,90(5):1685-1691.
[11] Palomba S, Falbo A, La Sala GB.Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials[J]. BJOG,2013, 120(3):267-276.
[12] Huang X, Wang P, Tal R, et al.A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures[J]. Int J Gynaecol Obstet,2015, 131(2):111-116.
[13] Amir H, Yaniv D, Hasson J, et al.Cabergoline for redu-cing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial[J]. J Reprod Med,2015,60(1-2):48-54.
[14] Leitao VM, Moroni RM, Seko LM, et al.Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril,2014,101(3):664-675.
[15] Youssef MA, Al-Inany HG, Evers JL, et al. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome[J]. Cochrane Database Syst Rev,2011,(2):CD001302.
[16] El-Khayat W, Elsadek M.Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial[J]. Fertil Steril,2015, 103(1):101-105.
[17] Naredi N, Karunakaran S.Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome[J]. J Hum Reprod Sci,2013,6(4):248-252.
[18] Qublan HS, Al-Taani MI, Megdadi MF, et al.Multiple transvaginal ascitic fluid aspirations improves the clinical and reproductive outcome in patients undergoing in vitro fertilisation treatment complicated by severe early ovarian hyperstimulation syndrome[J]. J Obstet Gynaecol,2012, 32(4):379-382.
